In Dialysis Population

• Liposomal iron was effective and raised hemoglobin in 63% of dialysis population over a 4 week period. Presence of diabetes mellitus or raised CRP didn’t make significant difference.
• However, Tsat or ferritin levels remained unchanged.
• Ferisome was very well tolerated. Side effects were observed in only 8% (only constipation); (30-70% patients have adverse event due to oral iron).
• Iron injection was also well tolerated. 155 patients had minor reactions. Intravenous iron raised Tsat and ferritin in all patients.

In Nondialysis Patients

• Every 4th person in the world is anemic. Iron deficiency is the leading cause of anemia.
• In chronic kidney disease (CKD), this problem is further aggravated. Iron needs to be replaced in significant amounts.
• Patients experience lot of side effects by traditional formulations of oral iron.
• Intravenous iron is frequently given which corrects iron deficiency but carries risk of anaphylaxis and other side effects.
• Recently, a new liposomal preparation of iron pyrophosphate has come in vogue.
• We have used this oral preparation successfully at BLK Super Specialty Hospital, over last 2 years in more than 300 patients with promising results.